NDLI: Evaluation of Significance of Lymphocyte Subpopulations and Non-specific Serologic Markers in B-cell Non-Hodgkin’s Lymphoma Patients

Content Provider	Springer Nature Link
Author	Pósfai, Éva Irsai, Gábor Illés, Árpád Méhes, Gábor Marton, Imelda Molnár, Csaba Csípő, István Baráth, Sándor Gergely, Lajos
Copyright Year	2014
Abstract	The use of rituximab brought attention to the hosts’ immune system and to the microenvironment in non-Hodgkin’s lymphoma cases. Our aim was to identify prognostic factors that can be measured easily to indicate the current state of the patient’s immune status and possible reaction against malignant cells. In the retrospective analysis (2000–2008), 66 patients diagnosed with B-cell non-Hodgkin’s lymphomas were enrolled (40 women, 26 men; mean age: 51 years). White blood cells, lymphocytes, CD3 +; CD4 +; CD8 + T-cells, immunoglobulin types A; G; M, anti-cardiolipin antibody isotypes A; G; M; and levels of beta-2-microglobulin were measured before the initiation of the first cycle of chemotherapy, during and after 4-weeks treatment. As for CD 3+ T-lymphocytes, the absolute CD 3+ T –lymphocyte numbers were higher before (0.78 × 10$^{9}$/L) versus during (0.27 × 10$^{9}$/L) treatment, and increased percentages were detected in pre- (66.57 %) and post-treatment (75.32 %). Absolute numbers of CD 8+ T-lymphocyte levels showed reduction before (0.26 × 10$^{9}$/L) versus during (0.10 × 10$^{9}$/L) therapy, but were elevated after (0.28 × 10$^{9}$/L) treatment, while increased percentage before (21.99 %) versus after (29.85 %), and during (24.56 %) versus after (29.85 %) therapy were seen. Average white blood cell numbers were increased before (9.71 × 10$^{9}$/L) versus during (12.07 × 10$^{9}$/L) treatment, while decreased numbers could be observed, after (5.47 × 10$^{9}$/L) treatment. IgA levels were decreased before (2.51 g/L) versus after (1.63 g/L) therapy. IgG levels were higher before (12.25 g/L) vs. after (8.64 g/L) treatment. IgM levels were decreased before (1.76 g/L) and after (0.83 g/L) as well as before (1.76 g/L) versus during (0.73 g/L) treatment. Anti-cardiolipin antibody type A level were decreased before (2.76 U/ml) versus after (2.49 U/ml) treatment. Decreased level of beta-2-microglobulin could be observed before (2.91 mg/L) versus post (2.28 mg/L) chemotherapy. Findings may provide better insight into the effects of immuno-chemotherapy on the hosts’ immune system.
Starting Page	649
Ending Page	654
Page Count	6
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	20
Issue Number	3
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	2014-02-01
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Lymphocyte subpopulations Non-specific serologic markers Non-Hodgkin’s lymphoma Immuno-chemotherapy Host immune system Cancer Research Oncology Pathology Immunology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients.

Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP

Primary effusional lymphoma: A new non-hodgkin’s lymphoma entity

Prognostic Significance of Cell Proliferation and Apoptosis-Regulating Proteins in Epstein-Barr Virus Positive and Negative Pediatric Non-Hodgkin’s Lymphoma

ABVD as the Treatment Option in Advanced Hodgkin’s Lymphoma Patients Older than 45 Years

Intra-tumoral cytolytic cells: Pattern of distribution in B-cell non Hodgkin’s lymphoma

Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin’s lymphoma

Tissue-Specific Homing of Immune Cells in Malignant Skin Tumors

Prolonged Survival Using Anti-CD20 Combined Chemotherapy in Primary Prostatic Intravascular Large B-cell Lymphoma

Evaluation of Significance of Lymphocyte Subpopulations and Non-specific Serologic Markers in B-cell Non-Hodgkin’s Lymphoma Patients

Similar Documents

Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients.

Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP

Primary effusional lymphoma: A new non-hodgkin’s lymphoma entity

Prognostic Significance of Cell Proliferation and Apoptosis-Regulating Proteins in Epstein-Barr Virus Positive and Negative Pediatric Non-Hodgkin’s Lymphoma

ABVD as the Treatment Option in Advanced Hodgkin’s Lymphoma Patients Older than 45 Years

Intra-tumoral cytolytic cells: Pattern of distribution in B-cell non Hodgkin’s lymphoma

Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin’s lymphoma

Tissue-Specific Homing of Immune Cells in Malignant Skin Tumors

Prolonged Survival Using Anti-CD20 Combined Chemotherapy in Primary Prostatic Intravascular Large B-cell Lymphoma

Evaluation of Significance of Lymphocyte Subpopulations and Non-specific Serologic Markers in B-cell Non-Hodgkin’s Lymphoma Patients